"Apolipoprotein C-III" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2).
| Descriptor ID |
D053305
|
| MeSH Number(s) |
D10.532.091.400.875 D12.776.070.400.400.875 D12.776.521.120.400.875
|
| Concept/Terms |
Sialyl Apo C-III- Sialyl Apo C-III
- Apo C-III, Sialyl
- Sialyl Apo C III
- Sialyl Apolipoprotein C-III
- Apolipoprotein C-III, Sialyl
- Sialyl Apolipoprotein C III
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein C-III".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein C-III".
This graph shows the total number of publications written about "Apolipoprotein C-III" by people in this website by year, and whether "Apolipoprotein C-III" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 3 | 0 | 3 |
| 2018 | 5 | 1 | 6 |
| 2019 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Apolipoprotein C-III" by people in Profiles.
-
Targeting RNA to lower triglycerides: long strides from short molecules. Eur Heart J. 2019 09 01; 40(33):2797-2800.
-
Apolipoprotein C-III Strongly Correlates with Activated Factor VII-Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation. Thromb Haemost. 2019 Feb; 119(2):192-202.
-
Vitamin D derivatives inhibit hepatitis C virus production through the suppression of apolipoprotein. Antiviral Res. 2018 12; 160:55-63.
-
Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2018 11; 50(7):565-575.
-
Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease. Clin Chem Lab Med. 2018 08 28; 56(9):1542-1550.
-
Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen. Rev Cardiovasc Med. 2018 Mar 30; 19(1):13-19.
-
A novel index including SNPs for the screening of nonalcoholic fatty liver disease among elder Chinese: A population-based study. Medicine (Baltimore). 2018 Mar; 97(13):e0272.
-
Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. J Clin Lipidol. 2018 May - Jun; 12(3):801-809.
-
Hepatitis B virus inhibits the in vivo and in vitro synthesis and secretion of apolipoprotein C3. Lipids Health Dis. 2017 Nov 13; 16(1):213.
-
ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. Curr Atheroscler Rep. 2017 Nov 09; 19(12):62.